XNASGANX
Market cap64mUSD
Jan 08, Last price
2.44USD
1D
7.49%
1Q
23.86%
IPO
-80.00%
Name
Gain Therapeutics Inc
Chart & Performance
P/E
—
P/S
1,172.91
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.30%
Rev. gr., 5y
21.77%
Revenues
55k
-60.62%
Net income
-22m
L+26.59%
CFO
-19m
L+28.41%
Earnings
Mar 24, 2025
Profile
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 55 -60.62% | 140 -15.08% | ||||
Cost of revenue | 22,389 | 17,981 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (22,334) | (17,841) | ||||
NOPBT Margin | ||||||
Operating Taxes | 79 | 93 | ||||
Tax Rate | ||||||
NOPAT | (22,413) | (17,934) | ||||
Net income | (22,268) 26.59% | (17,591) 26.64% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 12,730 | |||||
BB yield | -29.97% | |||||
| Debt | ||||||
Debt current | 348 | 337 | ||||
Long-term debt | 1,138 | 1,608 | ||||
Deferred revenue | 95 | |||||
Other long-term liabilities | 307 | 158 | ||||
Net debt | (15,308) | (20,135) | ||||
| Cash flow | ||||||
Cash from operating activities | (18,866) | (14,692) | ||||
CAPEX | (15) | (119) | ||||
Cash from investing activities | 10,223 | (14,775) | ||||
Cash from financing activities | 12,641 | (79) | ||||
FCF | (22,194) | (17,731) | ||||
| Balance | ||||||
Cash | 16,795 | 20,139 | ||||
Long term investments | 1,941 | |||||
Excess cash | 16,792 | 22,073 | ||||
Stockholders' equity | (60,535) | (38,479) | ||||
Invested Capital | 74,543 | 58,683 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 13,011 | 11,883 | ||||
Price | 3.27 4.31% | 3.13 -42.36% | ||||
Market cap | 42,482 14.21% | 37,195 -32.62% | ||||
EV | 27,174 | 17,060 | ||||
EBITDA | (22,250) | (17,777) | ||||
EV/EBITDA | ||||||
Interest | 247 | |||||
Interest/NOPBT | ||||||